Detalles de la búsqueda
1.
Characterization of Clostridioides difficile isolates recovered from two Phase 3 surotomycin treatment trials by restriction endonuclease analysis, PCR ribotyping and antimicrobial susceptibilities.
J Antimicrob Chemother
; 75(11): 3120-3125, 2020 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32747931
2.
Analysis of Clostridium difficile biofilms: imaging and antimicrobial treatment.
J Antimicrob Chemother
; 73(1): 102-108, 2018 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29029221
3.
Molecular epidemiology of Clostridioides (Clostridium) difficile strains recovered from clinical trials in the US, Canada and Europe from 2006-2009 to 2012-2015.
Anaerobe
; 53: 38-42, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-29886050
4.
Enteric microbiome profiles during a randomized Phase 2 clinical trial of surotomycin versus vancomycin for the treatment of Clostridium difficile infection.
J Antimicrob Chemother
; 72(12): 3453-3461, 2017 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28927227
5.
Comparison of Clostridium difficile minimum inhibitory concentrations obtained using agar dilution vs broth microdilution methods.
Anaerobe
; 44: 73-77, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28188880
6.
Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes.
Antimicrob Agents Chemother
; 60(6): 3519-23, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27021314
7.
Impact of Surotomycin on the Gut Microbiota of Healthy Volunteers in a Phase 1 Clinical Trial.
Antimicrob Agents Chemother
; 60(4): 2069-74, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26787687
8.
Effect of Surotomycin, a Novel Cyclic Lipopeptide Antibiotic, on Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice.
Antimicrob Agents Chemother
; 60(6): 3333-9, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26976870
9.
Effect of Fidaxomicin versus Vancomycin on Susceptibility to Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice.
Antimicrob Agents Chemother
; 60(7): 3988-93, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27090175
10.
Impact of Variations in Test Method Parameters on In Vitro Activity of Surotomycin against Clostridium difficile and Surotomycin Quality Control Limits for Broth Microdilution and Agar Dilution Susceptibility Testing.
J Clin Microbiol
; 54(3): 749-53, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26677246
11.
Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial.
J Antimicrob Chemother
; 71(10): 2964-71, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27432604
12.
Discovery and development of surotomycin for the treatment of Clostridium difficile.
J Ind Microbiol Biotechnol
; 43(2-3): 195-204, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26670919
13.
Mutations associated with reduced surotomycin susceptibility in Clostridium difficile and Enterococcus species.
Antimicrob Agents Chemother
; 59(7): 4139-47, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25941217
14.
Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficile.
Antimicrob Agents Chemother
; 59(9): 5165-70, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26055381
15.
Effects of surotomycin on Clostridium difficile viability and toxin production in vitro.
Antimicrob Agents Chemother
; 59(7): 4199-205, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25941230
16.
Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium.
Antimicrob Agents Chemother
; 58(7): 3976-82, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24798273
17.
The capping domain in RalF regulates effector functions.
PLoS Pathog
; 8(11): e1003012, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-23166491
18.
Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against Clostridioides difficile infection challenge in vivo.
World J Gastrointest Pathophysiol
; 14(4): 71-85, 2023 Aug 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-37727283
19.
ADS024, a single-strain live biotherapeutic product of Bacillus velezensis alleviates dextran sulfate-mediated colitis in mice, protects human colonic epithelial cells against apoptosis, and maintains epithelial barrier function.
Front Microbiol
; 14: 1284083, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38268707
20.
ADS024, a Bacillus velezensis strain, protects human colonic epithelial cells against C. difficile toxin-mediated apoptosis.
Front Microbiol
; 13: 1072534, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36704560